Tag:
Amgen
Latest Headlines
Latest Headlines
Amgen's Xgeva gets new approval, just not one it wants most
Amgen has gotten an FDA approval for an expanded use of its drug Xgeva, just not the one it covets most. The drug was approved Thursday for treatment of the rare giant cell tumor of the bone (GCTB).
Amgen notches positive PhIII results for top cancer drug
Once again, Amgen's R&D chief Sean Harper has Roger Perlmutter to thank for a positive late-stage outcome on one of the Big Biotech's top cancer prospects.
Cheaper generic combo found as effective in RA as blockbuster Enbrel
Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.
Amgen's big Asian push triggers $75M heart drug pact for Japan
Amgen's new Asia strategy is paying off for one of its development partners. Shares of Cytokinetics surged 18% this morning after Amgen agreed to hand over $25 million in cash and up to $50 million in royalties in exchange for the Japanese rights to a heart drug now on the threshold of Phase III testing.
Amgen trumpets T-Vec oncolytic virus results from PhIII melanoma study
Interim results from Amgen's Phase III trial demonstrated the ability of talimogene laherparepvec, the oncolytic virus known as T-Vec, to shrink tumors while delivering some early signs of improved survival rates for melanoma patients.
Amgen forges ahead in Japan with Astellas joint venture
Amgen has seemed sorely in need of an Asian expansion strategy as competitors put down eastern roots and seemed to pass it by. But with an agreement this morning with Astellas Pharma to establish a new joint venture in Japan, the world's biggest biotech showed it won't be left behind.
Sights set on Asia, Amgen sets up JV development deal with Astellas
Just a few months after Amgen execs lamented a big Asian gap in their global strategy, the Big Biotech company has joined hands with Astellas to set up a new joint venture in Japan. Amgen is contributing 5 experimental-stage programs to the JV, including their late-stage anti-PCSK9 program for the cholesterol drug AMG-145.
Worker hurt in 'flash fire' at Amgen facility
A worker at an Amgen research facility in South San Francisco has been hospitalized after a "flash fire" involving hazardous materials.
Amgen, Novartis aim to fuel biotech startups in alliances with Atlas Venture
For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Amgen forges Chinese JV for Vectibix
The China drug market is getting trickier but that is not stopping the big names of biotech and pharma from plowing ahead with tie-ups of various kinds to sell into the enormous market. Amgen today said it is ready to attack the Chinese market with one of its cancer drugs.
